Cancer immunotherapy in the form of immune checkpoint inhibitors and cellular therapies
has improved the treatment and prognosis of many patients. Nevertheless, most cancers are …

Dendritic cells (DCs) are a heterogeneous group of antigen-presenting innate immune cells
that regulate adaptive immunity, including against cancer. Therefore, understanding the …

Glioblastoma (GBM) is the most aggressive form of primary brain tumor, for which effective
therapies are urgently needed. Cancer cells are capable of evading clearance by …

Immune checkpoint blockade (ICB) has substantially improved the prognosis of patients with
cancer, but the majority experiences limited benefit, supporting the need for new therapeutic …

Immunosuppressive tumor microenvironments (TMEs) reduce the effectiveness of immune
responses in cancer. Mesenchymal stromal cells (MSCs), precursors to cancer-associated …

Cell surface glycosylation has a variety of functions, and its dysregulation in cancer
contributes to impaired signaling, metastasis and the evasion of the immune responses …

Targeted protein degradation is an emerging strategy for the elimination of classically
undruggable proteins. Here, to expand the landscape of targetable substrates, we designed …

Recent advances in cancer immunology have enabled the discovery of promising
immunotherapies for various malignancies that have shifted the cancer treatment paradigm …

Background Pancreatic ductal adenocarcinoma (PDAC) is one of the deadliest cancers.
Despite the successful application of immune checkpoint blockade in a range of human …

Despite recent advances in cancer immunotherapy, pancreatic ductal adenocarcinoma
(PDAC) remains unresponsive due to an immunosuppressive tumor microenvironment …